ROR1 and B-cell chronic lymphocytic leukemia: Importantly, Lyn inhibition by Dasatinib was capable to attenuate the increase in the ROR1 surface levels during migration (Figure 5F) — despite variability among patients: Dasatinib treatment significantly reduced ROR1 dynamics in those CLL patients that upregulated their surface ROR1 during cell migration more than 3-fold.